Chapter 19: Has Genomics Failed to Deliver?

Has genomics failed to deliver? By 2000, the human genome had largely been sequenced, and by 2001, the first human genome map had been generated. The science and medical communities were very excited about the possibility of thousands of new genomics-derived drugs entering product development pipelines. One of the key goals of early genomics companies was to quickly transform into pharmaceutical concerns. The founders of these companies argued that thanks to the high-throughput genomics and bioinformatics tools that could be used to analyze huge stretches of DNA or masses of proteins, they would be able to identify completely novel targets and leap ahead of their competitors in the race to cure many diseases. Most of these companies set their sites on a wide range of targets; rather than focusing on specific indications, they planned to use their tools to examine hundreds, or even thousands, of potential targets. From that huge ...

Users without subscription are not able to see the full content on this title. Please, subscribe or login to access all content on this website.

• Buy The Book